Innovation in Cancer, Infectious Disease Research
Stephen Isaacs, CEO of Aduro Biotech, at the launch of the IVRI on March 23. (Peg Skorpinski photos)
Doctors have had great success using vaccines to boost the immune system to fight infectious diseases like smallpox and measles, but only recently have immune system boosters been tried against cancer.
The growing success of such attempts — a booming field called immunotherapy that was pioneered at UC Berkeley — proves that studying the way the immune system deals with these two types of invaders, cancer cells and pathogens, could greatly improve therapies for both.
This is the goal of UC Berkeley’s Immunotherapeutics and Vaccine Research Institute, launched last year to explore the commonalities of cancer and infectious disease, and use discoveries in one area to improve treatment in the other.
Russell Vance and his colleagues Daniel Portnoy, Michael Eichberg and IVRI faculty director David Raulet argued for this approach in a perspective piece appearing in the current issue of the journal Science Immunology.
“The two fields are dramatically intertwined … and have much to learn from each other. More interactiveness is likely to fuel major strides in both fields,” Raulet told the website Healthline News last week. In addition to directing IVRI, Raulet is the Esther and Wendy Schekman Chair in basic cancer biology.
In the video above, Vance, an associate professor of molecular and cell biology and a Howard Hughes Medical Institute investigator, and IVRI researcher Sarah Stanley discuss how basic discoveries in one field trigger insights in the other. Stanley is an assistant professor of molecular and cell biology and a tuberculosis researcher.
Consuming Low-Calorie Sweeteners May Predispose Overweight Individuals to DiabetesNews
Consumption of low-calorie sweeteners could promote metabolic syndrome and predispose people to prediabetes and diabetes, particularly in individuals with obesity, a new study on human fat-derived stem cells and fat samples suggests.READ MORE
Huntsman Cancer Institute Joins National Clinical Trial Targeting AMLNews
Huntsman Cancer Institute (HCI) at the University of Utah (U of U) has been selected to participate in the Beat AML Master Trial, an innovative clinical trial sponsored by The Leukemia & Lymphoma Society (LLS). The clinical trial is testing several new targeted therapies for the treatment of patients with acute myeloid leukemia (AML). HCI is the only facility in the Mountain West offering this trial to AML patients.READ MORE
Comments | 0 ADD COMMENT
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018
International Conference on Molecular Biology and Stem Cells
Aug 13 - Aug 15, 2018
World Congress on Plant Science and Molecular Biology
Sep 12 - Sep 13, 2018